Picture of Bioventix logo

BVXP Bioventix Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareBalancedSmall CapHigh Flyer

Momentum

Relative Strength (%)
1m+9.16%
3m+28.24%
6m+22.46%
1yr+24.41%
Volume Change (%)
10d/3m-54.28%
Price vs... (%)
52w High-0.96%
50d MA+13.35%
200d MA+25.98%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)28.24
PEG Ratio (f)4.28
EPS Growth (f)7.06%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value21.42
Price to Tang. Book21.42
Price to Free Cashflow33.16
Price to Sales20.16
EV to EBITDA24.77

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital83.04%
Return on Equity70.1%
Operating Margin78.29%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202430th Jun 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Bioventix EPS forecast chart

Profile Summary

Bioventix plc is a United Kingdom-based biotechnology company. The Company specializes in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. It has created a sheep hybridoma technology to produce stable and productive cell lines that secrete sheep monoclonal antibodies (SMAs) of very high affinity. Its recombinant FAbs are modified to enable simple conjugation to enzymes (HRP, AP) or biotinylation or association as dimeric FAb2. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function, and drug abuse. It provides ELISA Kits to monitor human exposure to industrial pollutants. It supplies antibody products and services to clinical diagnostics companies.

Directors

Last Annual
June 30th, 2023
Last Interim
June 30th, 2023
Incorporated
October 7th, 2003
Public Since
April 29th, 2014
No. of Employees
16
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
5,219,656

BVXP Share Price Performance

Upcoming Events for BVXP

Half Year 2024 Bioventix PLC Earnings Release

Similar to BVXP

Picture of 4Basebio logo

4Basebio

gb flag iconLondon Stock Exchange

Picture of Allergy Therapeutics logo

Allergy Therapeutics

gb flag iconLondon Stock Exchange

Picture of Arecor Therapeutics logo

Arecor Therapeutics

gb flag iconLondon Stock Exchange

Picture of Avacta logo

Avacta

gb flag iconLondon Stock Exchange

Picture of Batm Advanced Communications logo

Batm Advanced Communications

gb flag iconLondon Stock Exchange

FAQ